Celgene : CELG

All CELG Articles

433 Articles

Lee Jackson | Nov 1, 2014 at 9:15 AM EDT

Top Stocks Sold as Insiders Take Advantage of Huge Market Rally

Insider sellers have been noticeably absent for most of the month of October. Nothing like a good old-fashioned stock market…

Chris Lange | Oct 27, 2014 at 10:30 AM EDT

Biotech Short Interest Becomes Stock Specific

Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.

Chris Lange | Oct 23, 2014 at 2:39 PM EDT

Will Celgene Become the Next $100 Billion Biotech Stock?

ThinkstockDoes Celgene Corporation (NASDAQ: CELG) have what it takes to make it to a $100 billion market cap? Some analysts…

Lee Jackson | Oct 13, 2014 at 8:40 AM EDT

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech…

Chris Lange | Oct 10, 2014 at 10:10 AM EDT

Short Interest in Biotech Becomes Company Specific

The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the…

Jon C. Ogg | Oct 6, 2014 at 8:25 AM EDT

Top Analyst Upgrades and Downgrades: Celgene, Enterprise, Meritage, Mobileye, Qlik and More

These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. on Monday, October 6, 2014.

Lee Jackson | Oct 2, 2014 at 8:55 AM EDT

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.

Lee Jackson | Sep 29, 2014 at 8:30 AM EDT

3 Likely Biotech Buyout Candidates

A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could…

Jon C. Ogg | Sep 25, 2014 at 10:50 AM EDT

Short Sellers Make Moves in Key Biotech Stocks

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most…

Chris Lange | Sep 11, 2014 at 9:20 AM EDT

Short Sellers Remain Vigilant Against Biotechs

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest…

Lee Jackson | Sep 9, 2014 at 8:30 AM EDT

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy…

Lee Jackson | Sep 8, 2014 at 9:10 AM EDT

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

SunTrust Robinson Humphrey opens up coverage of the biotech sector with four top biotech stocks to buy and one Neutral-rated…

Chris Lange | Aug 27, 2014 at 10:25 AM EDT

Rising Short Interest in Biotech Stocks

Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.

Jon C. Ogg | Jul 20, 2014 at 9:11 AM EDT

Top Biotech Earnings Previews for the Week Ahead

ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector…

Lee Jackson | Jul 18, 2014 at 9:15 AM EDT

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

ThinkstockFor the third time in less than two weeks, one of the top brokerage firms we cover at 24/7 Wall Street…

1 … 18 19 20 21 22 … 29

Celgene : CELG

All CELG Articles

Top Stocks Sold as Insiders Take Advantage of Huge Market Rally

Biotech Short Interest Becomes Stock Specific

Will Celgene Become the Next $100 Billion Biotech Stock?

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Short Interest in Biotech Becomes Company Specific

Top Analyst Upgrades and Downgrades: Celgene, Enterprise, Meritage, Mobileye, Qlik and More

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

3 Likely Biotech Buyout Candidates

Short Sellers Make Moves in Key Biotech Stocks

Short Sellers Remain Vigilant Against Biotechs

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

Rising Short Interest in Biotech Stocks

Top Biotech Earnings Previews for the Week Ahead

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Celgene : CELG

All CELG Articles

Top Stocks Sold as Insiders Take Advantage of Huge Market Rally

Biotech Short Interest Becomes Stock Specific

Will Celgene Become the Next $100 Billion Biotech Stock?

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Short Interest in Biotech Becomes Company Specific

Top Analyst Upgrades and Downgrades: Celgene, Enterprise, Meritage, Mobileye, Qlik and More

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

3 Likely Biotech Buyout Candidates

Short Sellers Make Moves in Key Biotech Stocks

Short Sellers Remain Vigilant Against Biotechs

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

Rising Short Interest in Biotech Stocks

Top Biotech Earnings Previews for the Week Ahead

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%